Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T20:35:52.826Z.
Calculation as of: 2026-10-06T20:35:52.826Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5c882cca81b2c0fe2c09916b57b0a50c93804d18514abf2397940823ad07c5bd
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
CAMP4 Therapeutics Corporation
Market Cap
$248.50M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$247.62M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$247.27M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$241.94M
Price/FCF Ratio
N/A
TTM Avg
780.39
3Y Avg
474.08
5Y Avg
244.04
Market Cap
$255.88M
Price/FCF Ratio
455.31
TTM Avg
239.45
3Y Avg
256.85
5Y Avg
209.66
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| CAMP4 Therapeutics Corporation (CAMP) | $248.50M | N/A | N/A | N/A | N/A |
| Galectin Therapeutics Inc. (GALT)vs › | $247.62M | N/A | N/A | N/A | N/A |
| Sol-Gel Technologies Ltd. (SLGL)vs › | $247.27M | N/A | N/A | N/A | N/A |
| Upstream Bio, Inc. (UPB)vs › | $249.79M | N/A | N/A | N/A | N/A |
| Lifecore Biomedical, Inc. (LFCR)vs › | $241.94M | N/A | 780.39 | 474.08 | 244.04 |
| Q32 Bio Inc. (QTTB)vs › | $241.39M | N/A | 8.17 | 8.17 | 8.17 |
| Quantum-Si incorporated (QSI)vs › | $241.34M | N/A | N/A | N/A | N/A |
| Anika Therapeutics, Inc. (ANIK)vs › | $255.88M | 455.31 | 239.45 | 256.85 | 209.66 |
| AC Immune S.A. (ACIU)vs › | $256.47M | N/A | 5.28 | 5.50 | 5.50 |
| Century Therapeutics, Inc. (IPSC)vs › | $239.02M | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
